Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment ...Middle East

Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and...

Hence then, the article about insilico medicine and hygtia therapeutics enter new global strategic collaboration to co develop novel brain penetrant nlrp3 inhibitor for cns diseases treatment was published today ( Wednesday 21/01/2026 - 03:17 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment )

Also on site :

• Hundreds of flights delayed at O'Hare after pipe burst at air traffic control tower
• Karamo Brown Skips 'Queer Eye' Interviews and Says He Felt 'Mentally and Emotionally Abused' for Years 
• Humans&, a ‘human-centric’ AI startup founded by Anthropic, xAI, Google alums, raised $480M seed round